Antidiabetic Potential of Prosopis farcta Roots: In Vitro Pancreatic Beta Cell Protection, Enhancement of Glucose Consumption, and Bioassay-Guided Fractionation

Behzad Shahbazi; Saba Feyzmand; Fataneh Jafari; Nastaran Ghiasvand; Gholamreza Bahrami; Ali Fattahi; Solomon Habtemariam; Seyed-Mohammad Nabavi; Yalda Shokoohinia

doi:10.1155/2020/8048273

Antidiabetic Potential of Prosopis farcta Roots: In Vitro Pancreatic Beta Cell Protection, Enhancement of Glucose Consumption, and Bioassay-Guided Fractionation

Evid Based Complement Alternat Med. 2020 Jan 20:2020:8048273. doi: 10.1155/2020/8048273. eCollection 2020.

Authors

Behzad Shahbazi¹, Saba Feyzmand², Fataneh Jafari¹, Nastaran Ghiasvand¹, Gholamreza Bahrami¹, Ali Fattahi³, Solomon Habtemariam⁴, Seyed-Mohammad Nabavi⁵, Yalda Shokoohinia^{1

6}

Affiliations

¹ Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
² Student Research Committee, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.
³ Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
⁴ Pharmacognosy Research Laboratories & Herbal Analysis Services UK, University of Greenwich, Central Avenue, Chatham-Maritime, Kent ME4 4TB, Gillingham, UK.
⁵ Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran 14359-16471, Iran.
⁶ Ric Scalzo Research Center, Southwest College of Naturopathic Medicine, Tempe, AZ, USA.

Abstract

By using the streptozotocin- (STZ-) induced cytotoxicity in β-TC3 cells as an assay model, a bioassay-guided fractionation study was employed to isolate and characterize the potential antidiabetic principles of roots of Prosopis farcta. A combination of open column chromatography on reverse-phase silica gel using a water-ethanol gradient (10 : 90 to 100 : 0) followed by HPLC-based fractionation led to an active compound that appears to be composed of carbohydrate/sugar. When cell viability under STZ was reduced to 49.8 ± 4% (mean ± SD), treatment with the active compound at the concentration of 0.5 mg/mL either as a coadministration or a pretreatment improved the viability to 93 ± 1.9% and 91.5 ± 7%, respectively. The reduction in the mitochondrial membrane potential by STZ (47.34 ± 8.9% of control) was similarly recovered to 84.5 ± 4.3 (coadministration) and 88 ± 5.5% (pretreatment) by the active fraction. The bioassay-guided fractionation, β-cell protective effect, and increased glucose consumption (up to 1.49-fold increase) in hepatocytes by the extracts and active fraction are also discussed.